Potassium Gluconate, Magnesium Gluconate

Pharmacological properties

Rhythmocore is an original combination drug with metabolic, membrane-stabilizing, antioxidant and antiarrhythmic effects.

The pronounced metabolic activity of the rhythmocore is due to the activation of redox enzymes, increased intracellular levels of ATP and creatine phosphate. These effects help optimize the functioning of ionic cell pumps. One of the mechanisms of action of Rhythmocore on cells under conditions of ischemia and hypoxia is the inhibition of the intensity of free radical oxidation of proteins and lipid peroxidation. The use of the drug in conditions associated with the activation of free radical reactions is accompanied by a decrease in the permeability of cell membranes.

The drug has an antiarrhythmic effect and potentiates the clinical effectiveness of antiarrhythmic drugs.

The components of the drug are rapidly adsorbed in the digestive tract. The maximum concentration in the blood is determined after 1-1.5 hours. The metabolic products of the drug are excreted by the kidneys.

Indications

Complex treatment: coronary heart disease; cardiopsychoneurosis; myocardial infarction; heart rhythm disturbances (atrial and ventricular extrasystolic arrhythmia), especially associated with a deficiency of magnesium and potassium ions; inflammatory diseases of the heart muscle (myocarditis); myocardiopathies; disturbances in electrolyte metabolism (correction of the level of magnesium and potassium ions); liver diseases of various etiologies, to increase the resistance of hepatocytes to various pathological effects (viral, inflammatory, intoxication); chronic fatigue syndrome.

Application

Usually, the capsules are taken orally (with a small amount of water), 1-2 capsules 10-15 minutes before meals 3-4 times a day. when the therapeutic effect is achieved (usually after 5-7 days), the dose of the drug is reduced to 1 capsule 3 times a day. the method of application, the dose of the drug and the duration of the course of treatment are set individually.

If it is necessary to quickly achieve a therapeutic effect, treatment begins with the use of an injectable form of the drug.

As an antiarrhythmic drug, Rhythmocor is used for atrial and ventricular extrasystolic arrhythmias, cardiac arrhythmias associated with hypomagnesemia and hypokalemia, for the prevention of paroxysmal atrial fibrillation (regardless of heart rate). The simultaneous use of the drug together with cardiac glycosides reduces the risk of arrhythmogenic manifestations.

In case of chronic fatigue syndrome and for the prevention of migraine attacks, the drug is used 1 capsule 3 times a day for 3-6 months.

In children aged 3 to 6 years, the drug is used 1 capsule 2 times a day, in children 6-12 years old - 1 capsule 3 times a day, in children over the age of 12 years, the drug is prescribed, as in adults.

Adults are prescribed iv 10–10 ml of Rhythmocor solution i.v. 1-2 times a day, previously diluted in 10 ml of 0.9% sodium chloride solution or 5% dextrose solution. The drug is also used intravenously: 5–20 ml of the drug solution is diluted in 50–400 ml of 0.9% sodium chloride solution or 5% dextrose solution. The course of treatment is 10-14 days.

For the treatment of pirouette type tachycardia, the drug is administered iv, in a jet of 10–20 ml of a solution of a drug previously diluted in 10 ml of 0.9% sodium chloride solution or 5% dextrose solution, after which they switch to iv drip infusion: 5–20 ml of the drug solution is diluted in 50–400 ml of 0.9% sodium chloride solution or 5% dextrose solution.

For children 1-3 years old, the drug is prescribed at the rate of 1-2 ml of the drug solution for 1 year of life, 1-2 times a day, diluted in 5-10 ml of 0.9% sodium chloride solution or 5% solution dextrose;

children 3-6 years old - at a dose of 5 ml of a solution of the drug 1-2 times a day, diluted in 10 ml of 0.9% sodium chloride solution or 5% dextrose solution;

children 6-12 years old - 5-10 ml of the drug solution 1-2 times a day, diluted in 10 ml of 0.9% sodium chloride solution or 5% dextrose solution;

for children over 12 years of age, the drug is prescribed in the same dose as adults.

Contraindications

Cardiogenic shock, systolic pressure in adults below 90 mm Hg. Art., atrioventricular block of the III degree, coma of unknown etiology, decompensated forms of diabetes mellitus, acute and chronic renal failure of the II – IV degree. rhythmocor is contraindicated in hyperkalemia and hypermagnesemia.

Side effects

The drug is well tolerated, side effects develop very rarely. in some cases, in individuals with increased individual sensitivity to the drug during its use, dizziness may be associated with the effect of the first dose. in these cases, the dose of the drug is reduced or canceled. after stopping the drug, side effects quickly disappear.

special instructions

When prescribing rhythmocore to patients with diabetes mellitus, it is necessary to take into account the possibility of determining a false-raised level of glucose in the blood when using the orthotoluidine method in connection with the presence of gluconic acid. during the treatment with rhythmocore, it is necessary to control the level of potassium and magnesium in the blood serum.

During pregnancy and lactation, the use of the drug is possible if the expected benefit to the mother outweighs the potential risk to the fetus.

One capsule of the drug contains 0.03 XE.

One ampoule (5 ml or 10 ml) contains, respectively, 0.008 or 0.016 XE.

Interactions

With the simultaneous use of rhythmocore with antiarrhythmic and antihypertensive drugs, one should take into account their mutual increase in activity. with the simultaneous use of the drug with potassium-sparing diuretics and APF inhibitors, it is necessary to monitor the level of potassium and magnesium in the blood serum. with simultaneous use with cardiac glycosides, the risk of their toxic effects on the heart is reduced.

Overdose

With oral administration, cases of overdose are not marked. perhaps increased manifestations of hypersensitivity to the drug, the development of hyperkalemia and hypermagnesemia.

Storage conditions

In a dry, dark place.